atopic dermatitis

[Pfizer, Inc.] Pfizer, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.

[Molecular Medicine Reports] The authors determined whether Lycopus lucidus Turcz (LLT) could improve 2,4‑dinitrochlorobenzene‑induced dermatitis and to verify the inhibitory effect of LLT on the expression of chemokines and pro‑inflammatory cytokines in the HaCaT immortalized keratinocyte cell line.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists showed that in atopic dermatitis, IL-4 and IL-13 stimulated the expression of 3β-hydroxysteroid dehydrogenase 1, a key rate-limiting enzyme in sex steroid hormone synthesis, predominantly expressed by sebaceous glands in human skin.

[Stem Cell Research & Therapy] Researchers investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood MSCs in atopic dermatitis.

[Eli Lilly and Company, Inc.] Eli Lilly and Company and Incyte announced that the US FDA will not meet the Prescription Drug User Fee Act action date for the supplemental new drug application for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).

[Frontiers in Cell and Developmental Biology] Researchers review the composition, structure and function of the ECM in cutaneous homeostasis, inflammatory skin diseases such as psoriasis and atopic dermatitis as well as infections as a paradigm for understanding its wider role in human health.